On Friday, August 7, 2020, Emergent BioSolutions Inc., a global life sciences company that offers specialized products to healthcare providers and governments to address medical needs and emerging public health threats, announced that it completed its previously announced offering of $450 million in aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by all of the company’s direct and indirect subsidiaries that guarantee debt under its credit facilities. Emergent BioSolutions has used the net proceeds of the offering to repay the $353 million outstanding under its $600 million revolving credit facility with the remainder to be used for general corporate purposes.

The WilmerHale team representing Emergent BioSolutions was led by Brian Johnson, Justin Ochs, Andrew Langworthy, Rob Isham, Morgan Monroe and Abena Ababio and included Bruce Manheim, Amy Null, Julie Hogan Rodgers, Timothy Silva and Seth Davis.